Evidence map›Paper›PMID 34485685›Full record

ArticleAdvanced therapeutics2021

Photothermal therapy combined with neoantigen cancer vaccination for effective immunotherapy against large established tumors and distant metastasis.

Jutaek Nam, Sejin Son, Kyung Soo Park, James J Moon

Open access · bronzeAbstract read
In one paragraph

Article in Advanced therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.International journal of biological sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Jutaek Nam *Department of Pharmaceutical Sciences, Biointerfaces Institute, University of Michigan.
Sejin Son *Department of Pharmaceutical Sciences, Biointerfaces Institute, University of Michigan.
Kyung Soo ParkDepartment of Biomedical Engineering, Biointerfaces Institute, University of Michigan.
James J MoonDepartment of Pharmaceutical Sciences, Department of Biomedical Engineering, Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48108, USA.
University of Michigan · USChonnam National University · KR

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Tissue Engineering and RegenerationT32DE007057 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DAVID H. KOHN · 1985 to 2026
$17.3M
Environmental Regulation of Cancer Stem Cell Plasticity in MetastasisU01CA210152 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAHANN, JOERG, LUKER, GARY D · 2017 to 2021
$3.6M
Novel nano-vaccine technology for inducing immunity against gliomasR01NS122536 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G, MOON, JAMES J. · 2021 to 2025
$2.6M
Novel biomaterials for IBD treatmentR01DK125087 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAMADA, NOBUHIKO, MOON, JAMES J. · 2020 to 2023
$2.5M
Elicitation of mucosal immune responses against HIVR01AI127070 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2016 to 2020
$2.3M
Nanomaterials for eliciting anti-tumor T-cells-Diversity SupplementR01CA210273 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOON, JAMES J. · 2017 to 2021
$2.2M
NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA210273NCI NIH HHS U01 CA210152NIAID NIH HHS HHSN272201300006CNIAID NIH HHS R01 AI127070NIDCR NIH HHS T32 DE007057NIDDK NIH HHS R01 DK125087NINDS NIH HHS R01 NS122536
6 · The paper itself

Abstract

Photothermal therapy (PTT) and neoantigen cancer vaccine each offers minimally invasive and highly specific cancer therapy; however, they are not effective against large established tumors due to physical and biological barriers that attenuate thermal ablation and abolish anti-tumor immunity. Here, we designed and performed comparative study using small (~ 50 mm

Indexed as

cancer vaccinenano-immunotherapyneoantigenPhotothermal therapy

Identifiers

PMID34485685
PMCPMC8412374
OpenAlexW3183707773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.